Navigation Links
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Date:10/19/2008

TR-701 Phase 1 Clinical Trial Results Disclosed

SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, TR-701, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in Washington, DC. Thirteen of the presentations focus on TR-701, a second generation oxazolidinone that recently commenced Phase 2 clinical studies.

"Acceptance of these presentations by the ICAAC committee highlights the interest in and value of the TR-701 program, the Trius pipeline, and our underlying technologies," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are especially pleased to provide details of our TR-701 Phase 1 clinical trial results that support the once-daily dosing and short course of therapy in our recently initiated Phase 2 study in complicated skin and skin structure infections (cSSSIs). It is also exciting to see that the results of studies by external investigators demonstrate the drug's increased potency and expanded spectrum of activity."

The presentations are as follows:

Saturday, October 25th

(Poster Summary Session, Ballroom A/B, 10:00 am - 12:00 pm)

-- Oral Presentation: Overview of TR-701 and TR-700 Posters and

Presentations

(Poster Session 23, 12:15 pm - 1:15 pm)

-- F1-334: Discovery and SAR of a Novel Series of Pyrimidine Antibacterials

Targeting Methionyl-tRNA Synthase (MetRS)

-- F1-335: In Vitro Activity of Rx100472 Against Clinically Important

Bacteria

-- F1-336: Advanced Microbiology Study of Rx100472, A Novel Methionyl-tRNA

Synthetase (MetRS) inhibitor

-- F1-337: In Vivo Efficacy of Rx100472, A Novel Methionyl-tRNA Synthetase

(MetRS) Inhibitor

Sunday, October 26th

(Poster Session 92, 11:15 am - 12:15 pm)

-- A-985: Pharmacodynamics of TR-701 in a Mouse Thigh Infection Model

Against S. aureus ATCC 33591, a Methicillin-Resistant Isolate

Monday, October 27th

(Poster Session 196, 11:15 am - 12:15 pm)

-- F1-2060: MICs of TR-700, the Active Moiety of the Novel Oxazolidinone

Prodrug TR-701, for Linezolid-Susceptible and - Resistant Enterococci

and Staphylcocci

-- F1-2061: TR-700, a Novel Oxazolidinone, Tested Against

Linezolid-Resistant Gram-Positive Species with Well-Characterized

Resistance Mechanisms

-- F1-2062: In Vitro Pharmacodynamics of TR-700, the Active Moiety of

Prodrug TR-701, a Novel Oxazolidinone, in a Kill-Curve Model

-- F1-2063: Human Pharmacokinetics of TR-700 after Ascending Single Oral

Doses of the Prodrug TR-701, a Novel Oxazolidinone Antibiotic

-- F1-2064: Human Pharmacokinetics of TR-700 after Multiple Oral Doses of

200 and 400 mg of TR-701, a Novel Oxazolidinone Antibiotic

-- F1-2065: In Vitro and In Vivo Efficacy of TR-701 and TR-700 Versus the

Linezolid- and Methicillin-Resistant Staphylococcus aureus cfr Strain

CM/05

-- F1-2066: Demonstration of TR-701 Efficacy in a Mouse Inhalation Anthrax

Model

-- F1-2067: Absence of a Pressor Response to Oral Tyramine in Conscious

Telemeterized Rats Treated with the Novel Oxazolidinone TR-701:

Comparison to Linezolid

-- F1-2068: Quality Control Parameters for TR-700 Broth Microdilution

Susceptibility Tests

-- F1-2069: Relative Potency of TR-700, the Active Moiety of Prodrug

TR-701, Against Selected Bacterial Pathogens and Provisional Disk Test

Criteria

-- F1-2069a ("Late Breaker"): Hematological Effects of TR-701,

Linezolid and Placebo Administered for 21 Days in Healthy Subjects

(Poster Session 197, 11:15 am - 12:15 pm)

-- F2-2070: Structure Guided Design of Pyrimidine Antibacterials Targeting

Methionyl-tRNA Synthase (MetRS)

Copies of these posters will be available on the Trius website following the ICAAC/IDSA meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, TR-701, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs being developed to treat serious infections including those caused by gram-negative bacterial pathogens. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
5. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
6. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... TEL AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. ... and immunology, today reports its financial results for the ... and achievements during the second quarter 2017 and to ... on multiple clinical development programs for the Company,s lead ... Phase 3 pivotal study with BL-8040 as novel stem ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology:
(Date:8/19/2017)... , ... August 18, 2017 , ... Western University of ... and education to launch the University’s new Center for Innovation on Wednesday, September 6, ... Education Center Lecture Hall 1, followed by a technology exhibition from 1 to 3 ...
(Date:8/19/2017)... York, New York (PRWEB) , ... August 19, ... ... Street Health has announced that it is the first organization with pending recognition ... CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live video ...
(Date:8/19/2017)... CA (PRWEB) , ... August 19, 2017 , ... Yesterday, ... the KKK by saying there are two sides. There are not two sides to ... way to rationalize violence and prejudice, and the NPEIV stands against all forms of ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... ... ... For Immediate Release                Contact: Julian Teixeira, August ... Seek Sex and Relationship Advice from their Fathers , ...
Breaking Medicine News(10 mins):